Already FDA-approved to treat major depression and migraines, TMS can now be marketed as a treatment for obsessive compulsive disorder Santa Barbara, Calif., September 21, 2018 – Transcranial Magnetic Stimulation (TMS) therapy is rapidly growing in popularity as a treatment [..]
Depression is a serious medical illness affecting more than 14 million American adults every year1. Often a debilitating disorder, depression results in a persistent state of sadness or loss of interest or pleasure which interferes with an individual’s thoughts, behavior, mood, and physical health.
In 2000, the economic burden of depression was estimated at $83.1 billion in the US2. Researchers estimate that by the year 2020, depression will be the second leading cause of disability worldwide.3
Brain activity is reduced in depression
|A PET scan measures vital functions such as blood flow, oxygen use and blood sugar (glucose) metabolism. You see in the above graphic the difference in brain activity of that a patient with depression attribution.|
Depression can be a lethal disease. In fact, each year in the US, over 30,000 people die by suicide, 60% of whom suffer from depression.4 Overall, women are almost twice as likely as men to suffer from depression; however, some experts feel that depression in men is under-reported.5 Depression can affect anyone; it has no racial, ethnic or socioeconomic boundaries. About two-thirds of those who experience an episode of depression will have at least one additional episode in their lives. While the exact cause of depression is not known, the leading scientific theory is that depression is caused by decreased activity in the neural networks of the brain that regulate mood.
More than 4 million patients do not receive adequate benefit from antidepressants and/or cannot tolerate the side effects caused by them.
For these patients, Transcranial Magnetic Stimulation (TMS) is a new depression treatment — a breakthrough for patients with drug resistant depression and mood disorders.References:
- Kessler, RC, et al. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 2005 Jun: 62 (6):617-27.
- Greenberg, PE, et al. The economic burden of depressive disorders in the United States: How did it change between 1990 and 2000? Journal of Clinical Psychiatry. 2003; 64 (12): 1465-1475.
- Murray CJ, Lopez AD. Evidence-based health policy – lessons from the Global Burden of Disease Study. Science. 1996; 274 (5288): 740-743.
- Heron, Melonie, et al. Deaths: Final Data for 2006. National Vital Statistics Reports, 57 (14). April 17, 2009.
- Kessler, RC, et al. The epidemiology of major depressive disorder; results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095-3105.